[go: up one dir, main page]

WO2024229454A3 - Nouvelles ergolines et procédés de traitement de troubles de l'humeur - Google Patents

Nouvelles ergolines et procédés de traitement de troubles de l'humeur Download PDF

Info

Publication number
WO2024229454A3
WO2024229454A3 PCT/US2024/027896 US2024027896W WO2024229454A3 WO 2024229454 A3 WO2024229454 A3 WO 2024229454A3 US 2024027896 W US2024027896 W US 2024027896W WO 2024229454 A3 WO2024229454 A3 WO 2024229454A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mood disorders
ergolines
novel
treating mood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/027896
Other languages
English (en)
Other versions
WO2024229454A2 (fr
Inventor
Andrew Carry KRUEGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilgamesh Pharmaceuticals Inc
Original Assignee
Gilgamesh Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilgamesh Pharmaceuticals Inc filed Critical Gilgamesh Pharmaceuticals Inc
Publication of WO2024229454A2 publication Critical patent/WO2024229454A2/fr
Publication of WO2024229454A3 publication Critical patent/WO2024229454A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés d'ergoline et leur utilisation dans le traitement de troubles de l'humeur. L'invention concerne également des compositions pharmaceutiques et des procédés de fabrication de divers composés d'ergoline.
PCT/US2024/027896 2023-05-04 2024-05-04 Nouvelles ergolines et procédés de traitement de troubles de l'humeur Pending WO2024229454A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363464044P 2023-05-04 2023-05-04
US63/464,044 2023-05-04
US202363545725P 2023-10-25 2023-10-25
US63/545,725 2023-10-25

Publications (2)

Publication Number Publication Date
WO2024229454A2 WO2024229454A2 (fr) 2024-11-07
WO2024229454A3 true WO2024229454A3 (fr) 2025-02-13

Family

ID=93333375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/027896 Pending WO2024229454A2 (fr) 2023-05-04 2024-05-04 Nouvelles ergolines et procédés de traitement de troubles de l'humeur

Country Status (1)

Country Link
WO (1) WO2024229454A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346346A1 (en) * 2017-02-09 2021-11-11 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
US20220160737A1 (en) * 2019-11-19 2022-05-26 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
WO2022153266A1 (fr) * 2021-01-15 2022-07-21 Beckley Psytech Limited Analogues d'ergoline
WO2022226408A1 (fr) * 2021-04-23 2022-10-27 Gilgamesh Pharmaceuticals, Inc. Nouvelles ergolines et procédés de traitement de troubles de l'humeur
WO2023018864A1 (fr) * 2021-08-12 2023-02-16 Psilosterics, Llc Agonistes hallucinogènes et non hallucinogènes du récepteur de la sérotonine et leurs procédés de fabrication et d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346346A1 (en) * 2017-02-09 2021-11-11 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
US20220160737A1 (en) * 2019-11-19 2022-05-26 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
WO2022153266A1 (fr) * 2021-01-15 2022-07-21 Beckley Psytech Limited Analogues d'ergoline
WO2022226408A1 (fr) * 2021-04-23 2022-10-27 Gilgamesh Pharmaceuticals, Inc. Nouvelles ergolines et procédés de traitement de troubles de l'humeur
WO2023018864A1 (fr) * 2021-08-12 2023-02-16 Psilosterics, Llc Agonistes hallucinogènes et non hallucinogènes du récepteur de la sérotonine et leurs procédés de fabrication et d'utilisation

Also Published As

Publication number Publication date
WO2024229454A2 (fr) 2024-11-07

Similar Documents

Publication Publication Date Title
WO2024091506A3 (fr) Nouvelles ergolines et procédés de traitement de troubles de l'humeur
MX2023012447A (es) Ergolinas novedosas y metodos para tratar los desordenes del humor.
EP4342469A3 (fr) Inhibiteurs d'autophagie d'amide de phénylaminopyrimidine et leurs procédés d'utilisation
EP4501407A3 (fr) Tryptamines spécifiques pour le traitement de troubles de l'humeur
CZ20011394A3 (cs) Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
IL156646A0 (en) Isoindole-imide compounds, compositions, and uses thereof
GEP20084572B (en) Novel quinoline derivatives
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EP4620472A3 (fr) Inhibiteurs de parp1 tricycliques et leurs utilisations
SI1747220T1 (sl) Substituirani 1H-pirolo(3,2-b, 3,2-c in 2,3-c)piridin-2-karboksamidi in sorodni analogi kot inhibitorji kazein kinaze I epsilon
WO2023201299A8 (fr) Compositions pharmaceutiques de protéines thérapeutiques et procédés d'utilisation
AU2024266519A9 (en) Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
AU2024266519A1 (en) Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2024229454A3 (fr) Nouvelles ergolines et procédés de traitement de troubles de l'humeur
WO2024059713A3 (fr) Compositions d'alcaloïdes de l'iboga et méthohdes de traitement
WO2024026484A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026481A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2021161023A8 (fr) Composés utiles dans l'inhibition de la cétohexokinase et leurs procédés de fabrication et d'utilisation
WO2025015149A3 (fr) Méthodes de traitement du cancer
DE69124380D1 (de) Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
WO2024026129A3 (fr) Dérivés aryle tricycliques, et compositions et procédés associés
CA3287057A1 (fr) Compositions et procédés pour le traitement de troubles liés à une déficience en protéine 1 de liaison à la syntaxine
WO2024243004A3 (fr) Compositions et procédés de traitement d'une lésion cérébrale traumatique
WO2023215913A3 (fr) Compositions et méthodes pour le diagnostic et le traitement de la covid-19 sévère et d'autres troubles auto-immuns inflammatoires
EP1631298B8 (fr) Glycosaminoglycanes destines au traitement de troubles emotionnels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24800724

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025023983

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2024800724

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2024800724

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024800724

Country of ref document: EP

Effective date: 20251204